Which UCTD features predict evolution to SLE?

High-titer anti-dsDNA, anti-Sm, anti-Ro with complement consumption, discoid or malar rash, cytopenia, lymphadenopathy, and photosensitivity in a woman <35 years predict evolution to SLE in UCTD.

What proportion of UCTD remains undifferentiated?

Approximately 30-40% evolve to defined CTD within 5 years; 30-40% remit; 20-30% remain as stable UCTD. The most common evolution is to SLE, pSS, or SSc depending on autoantibody profile.

What treatment is used for UCTD?

Hydroxychloroquine is the cornerstone of UCTD management, potentially delaying evolution to SLE. Symptom-directed therapy (NSAIDs, topical steroids). Immunosuppression added if evolving to defined CTD.

Undifferentiated Connective Tissue Disease (UCTD) Risk Score

Estimate the probability and timeline of UCTD evolution to a defined connective tissue disease (CTD) using clinical features, autoantibody profile, and disease duration. 30-40% of UCTD evolves within 5 years.

Use the full interactive calculator below, or

Related Calculators

ANA Titer/Pattern

Hyper-niche Medical

mRSS SSc